Investment Firms in Stamford, Connecticut, United States
Located in southwestern Connecticut, it serves as a strategic financial and corporate hub with notable activity in fintech and enterprise software. The ecosystem benefits from proximity to New York City's capital and a concentration of established financial services firms. Its venture landscape is characterized by a focus on later-stage growth rounds, particularly in B2B sectors.
Stamford, Connecticut, United States's investment landscape is shaped by Fintech, with 83% of its 6 investment firms focused on this sector. The most active by portfolio size are Oak HC/FT, Viking Global Investors, and Digital Currency Group.
Fintech dominates the investment landscape in Stamford, with 83% of investment firms focused on this sector.
Last updated: 13 March 2026
Investment Firms
6
Total Investments
195
Top Sector
Fintech
Top Stage
Series C
Top Investment Sectors in Stamford
The most popular sector focus among Stamford investment firms is Fintech, with 5 investment firms (83%) investing in the space. This is followed by Healthcare (3), Cybersecurity (3), Biotech & Life Sciences (2), Enterprise Software (2).
Investment Stages in Stamford
Stamford investment firms are most active at the Series C stage (5 investment firms). This is followed by Series A (5), Series B (4), Growth (3), Series D (3).
Oak HC/FT
Stamford, Connecticut, United States
79 investments
Series C, Series B
Healthcare, Fintech
Viking Global Investors
Stamford, Connecticut, United States
54 investments
Growth, Series A
Biotech & Life Sciences, Food & Agriculture, Healthcare …
Digital Currency Group
Stamford, Connecticut, United States
37 investments
Seed, Series A
Fintech, Crypto & Web3, AI …
DCG
Stamford, Connecticut, United States
10 investments
Seed, Series A
Cybersecurity, Crypto & Web3, Fintech …
Synchrony
Stamford, Connecticut, United States
8 investments
Series B, Series A
HR & Talent, E-Commerce & Marketplace, Developer Tools …
Braidwell LP
Stamford, Connecticut, United States
7 investments
Growth, Series C
Biotech & Life Sciences